What was approved and why it matters
Teva's Weltruza is the first once monthly subcutaneous olanzapine, built on Medincell's SteadyTeq technology. Unlike the older intramuscular olanzapine injection, Zyprexa Relprevv, it needs no loading dose, no oral overlap and no observation period after each injection.
Frequently asked questions
When was Weltruza approved?
The FDA approved Weltruza (olanzapine extended release injectable suspension) for adults with schizophrenia on 9 October 2026. Teva expects US availability within weeks.
How is Weltruza different from Zyprexa Relprevv?
Relprevv is an intramuscular olanzapine injection that requires at least 3 hours of observation in a registered facility after every dose because of a rare delirium and sedation reaction. Weltruza is given under the skin once a month with no required observation.
What are Weltruza's projected sales?
Zaash Labs' base case is about USD 562 million of US net revenue in 2031, within a range of USD 300 million to 900 million. Teva targets USD 1.5 to 2.0 billion peak sales for Uzedy and Weltruza combined.
Figures are company reported or from published sources unless marked as Zaash Labs estimates. Sources are listed in the executive summary and the full report. Market research to support business decisions; not investment advice.